Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
917 people get NVIV.OB articles and Market Currents by email alert.
Get email alerts on NVIV.OB »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
Bulls, Bears: The State Of CNS Companies In The Public MarketsOneMedPlace • Thu, Aug 16, 2012
To learn more about Seeking Alpha Pro, click here.
-
What Makes InVivo An Attractive Takeover TargetTakeover Analyst • Fri, Feb 10, 2012
-
Here's Why We Like InVivo TherapeuticsJason Napodano • Thu, Jan 19, 2012
-
InVivo Soon To Enter Clinical TestingJason Napodano • Tue, Nov 15, 2011
-
Bulls, Bears: The State Of CNS Companies In The Public MarketsOneMedPlace • Thu, Aug 16, 2012
-
Record 1Q Sales: Nerve Regeneration Products Gaining TractionCockrell Group • Wed, May 16, 2012
-
Analyzing Wednesday's Noteworthy Insider TradesGuruFundPicks • Thu, Apr 12, 2012
-
Stocks To Watch This WeekVFC's Stock House • Wed, Nov 23, 2011
There are no Transcripts on NVIV.OB.
There are no News articles on NVIV.OB.
NVIV.OB vs. ETF Alternatives
Company Description
Invivo Therapeutics Holdings Corp., a development stage company, focuses on developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries, peripheral nerve injuries, and other neurotrauma conditions. It intends to develop and commercialize biocompatible... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Monday, April 8, 10:56 AM InVivo Therapeutics (NVIV.OB +6.4%) trades sharply higher after offering to exchange outstanding warrants issued in 2010 for new warrants in connection with the company's intention to list on the NASDAQ or NYSE MKT. The company says the existing warrants would force it to report negative stockholder's equity, effectively precluding an uplist of the shares to a national securities exchange. 1 Comment [Healthcare, On the Move]
- Thursday, April 4, 10:49 AM InVivo Therapeutics (NVIV.OB +19.9%) rises sharply on heavy volume after announcing the FDA has approved its request for a Humanitarian Use Device designation for its biopolymer scaffolding product. The designation should help the company speed the product to market. A clinical trial submission is being reviewed by the FDA currently. 1 Comment [Healthcare, On the Move]
-
Joe Springer
$NVIV.OB Invivo is getting crushed with volume, some big name is dumping, hope you sold http://seekingalpha.com/a/hq0n #biotech #pharma - View all 0 replies
-
Joe Springer
Just a heads up, submitted a piece on #Invivo, says a strong sell with insiders dumping and refusal to uplist to Nasdaq $NVIV $NVIV.OB - View all 3 replies
-
-
Joe Springer: Right on, some of these guys go to the country club with shareholder money and issue new shares, you have to do your diligence
-
Scott Matusow
$NVIV.OB might see a move to $3 today. Been getting a lot of media coverage, even national exposure, keep and eye on it. - View all 4 replies
-
Scott Matusow: no, google " stock warrants" and what you find will explain it much better than I can in a short tweet thing like this :) -
-
Michael Kudrna
Napodano: Expecting Big Things From InVivo In 2012 $NVIV.OB $$ $IWM #KSMT #biotech http://bit.ly/wwxFm1 - View all 0 replies
LATEST REPLIES
-
Joe Springer
Just a heads up, submitted a piece on #Invivo, says a strong sell with insiders dumping and refusal to uplist to Nasdaq $NVIV $NVIV.OB - View all 3 replies
-
-
Joe Springer: Right on, some of these guys go to the country club with shareholder money and issue new shares, you have to do your diligence
-
Scott Matusow
$NVIV.OB might see a move to $3 today. Been getting a lot of media coverage, even national exposure, keep and eye on it. - View all 4 replies
-
Scott Matusow: no, google " stock warrants" and what you find will explain it much better than I can in a short tweet thing like this :) -




